ATE500833T1 - Pharmazeutische zusammensetzungen zur verhütung oder behandlung von hirnödemen - Google Patents

Pharmazeutische zusammensetzungen zur verhütung oder behandlung von hirnödemen

Info

Publication number: ATE500833T1
Authority: AT; Austria
Prior art keywords: preventing; cerebral edema; treating cerebral; alkyl; etifoxine
Prior art date: 2005-07-19

Application number

AT06291166T

Other languages

English (en)

Inventor

Guern Marie-Emmanuelle Le

Philippe Girard

Jean-Marie Gillardin

Laurence Berthon-Cedille

Bernard Hublot

Original Assignee

Biocodex

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-19

Filing date

2006-07-18

Publication date

2011-03-15

2006-07-18 Application filed by Biocodex filed Critical Biocodex

2011-03-15 Application granted granted Critical

2011-03-15 Publication of ATE500833T1 publication Critical patent/ATE500833T1/de

Links

206010048962 Brain oedema Diseases 0.000 title abstract 5
208000006752 brain edema Diseases 0.000 title abstract 5
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
125000000217 alkyl group Chemical group 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
CMLFRMDBDNHMRA-UHFFFAOYSA-N 2h-1,2-benzoxazine Chemical compound C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 abstract 2
125000003545 alkoxy group Chemical group 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
229960003817 etifoxine Drugs 0.000 abstract 2
125000001475 halogen functional group Chemical group 0.000 abstract 2
125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 2
RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 abstract 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
229930195725 Mannitol Natural products 0.000 abstract 1
241000700159 Rattus Species 0.000 abstract 1
DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 abstract 1
239000003242 anti bacterial agent Substances 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
229940125717 barbiturate Drugs 0.000 abstract 1
HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 abstract 1
230000003115 biocidal effect Effects 0.000 abstract 1
210000004556 brain Anatomy 0.000 abstract 1
239000000480 calcium channel blocker Substances 0.000 abstract 1
230000001966 cerebroprotective effect Effects 0.000 abstract 1
229960001284 citicoline Drugs 0.000 abstract 1
239000013066 combination product Substances 0.000 abstract 1
229940127555 combination product Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 abstract 1
229960003883 furosemide Drugs 0.000 abstract 1
239000003862 glucocorticoid Substances 0.000 abstract 1
239000000594 mannitol Substances 0.000 abstract 1
235000010355 mannitol Nutrition 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
239000000047 product Substances 0.000 abstract 1
CPRPKIMXLHBUGA-UHFFFAOYSA-N triethyltin Chemical compound CC[Sn](CC)CC CPRPKIMXLHBUGA-UHFFFAOYSA-N 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT06291166T 2005-07-19 2006-07-18 Pharmazeutische zusammensetzungen zur verhütung oder behandlung von hirnödemen ATE500833T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0507649A FR2888749B1 (fr)	2005-07-19	2005-07-19	Composition pharmaceutique destinee a la prevention ou au traitement des oedemes cerebraux

Publications (1)

Publication Number	Publication Date
ATE500833T1 true ATE500833T1 (de)	2011-03-15

Family

ID=35998401

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06291166T ATE500833T1 (de)	2005-07-19	2006-07-18	Pharmazeutische zusammensetzungen zur verhütung oder behandlung von hirnödemen

Country Status (5)

Country	Link
US (1)	US7569565B2 (de)
EP (1)	EP1745785B1 (de)
AT (1)	ATE500833T1 (de)
DE (1)	DE602006020525D1 (de)
FR (1)	FR2888749B1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007109289A1 (en) *	2006-03-20	2007-09-27	Xytis Inc.	Enantiomerically pure s-etifoxine, pharmaceutical compositions thereof and methods of their use
WO2007109288A2 (en) *	2006-03-20	2007-09-27	Xytis Inc.	Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use
FR2937552B1 (fr) *	2008-10-27	2011-05-06	Biocodex	Composition pharmaceutique destinee a la prevention ou au traitement du syndrome de sevrage alcoolique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1670772C3 (de)	1966-11-24	1978-04-20	Hoechst Ag, 6000 Frankfurt	4H-3,1-Benzoxazin-Derivate, deren Salze und pharmazeutische Präparate
DE3439055A1 (de) *	1984-10-25	1986-04-30	Hoechst Ag, 6230 Frankfurt	Substituierte 4h-3,1 benzoxazine und ein benzodiazepin-derivat enthaltendes arzneimittel
MXPA05011103A (es) *	2003-04-16	2005-12-12	Hoffmann La Roche	Compuestos de quinazolina.

2005
- 2005-07-19 FR FR0507649A patent/FR2888749B1/fr not_active Expired - Fee Related
2006
- 2006-07-18 US US11/488,068 patent/US7569565B2/en active Active
- 2006-07-18 DE DE602006020525T patent/DE602006020525D1/de active Active
- 2006-07-18 AT AT06291166T patent/ATE500833T1/de not_active IP Right Cessation
- 2006-07-18 EP EP06291166A patent/EP1745785B1/de active Active

Also Published As

Publication number	Publication date
EP1745785A1 (de)	2007-01-24
DE602006020525D1 (de)	2011-04-21
US20070021415A1 (en)	2007-01-25
US7569565B2 (en)	2009-08-04
EP1745785B1 (de)	2011-03-09
FR2888749A1 (fr)	2007-01-26
FR2888749B1 (fr)	2007-10-12

Similar Documents

Publication	Publication Date	Title
MX340965B (es)	2016-08-02	Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
BR0116299A (pt)	2004-03-02	Composto, composição farmacêutica, método para o tratamento ou profilaxia de uma infecção picornaviral em um mamìfero, e, uso de um composto
NO20052130L (no)	2005-04-29	Sterk inhibitor for HCV-serin-protease
BR0309342A (pt)	2005-02-15	Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
ATE457988T1 (de)	2010-03-15	A2a-adenosin-rezeptor-antagonisten
GEP20094723B (en)	2009-07-10	Tetraazabenzo [e] azulene derivatives and analogs thereof
BR0309343A (pt)	2005-02-15	Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
TW200420549A (en)	2004-10-16	Thiazole derivatives
ECSP077402A (es)	2007-05-30	Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
BR0315580A (pt)	2005-08-30	Derivados de metileno uréia
MA31142B1 (fr)	2010-02-01	Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
DE602005013793D1 (de)	2009-05-20	Thiazolderivate mit vap-1-hemmender wirkung
BR0315777A (pt)	2005-09-13	Uso de derivados de piperazina como antagonistas ccr1
BRPI0411673A (pt)	2006-08-08	composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
IL184116A0 (en)	2007-10-31	Use of thiazolidinone derivatives as antiangiogenic agents
BR0211171A (pt)	2004-08-10	Compostos quìmicos
BRPI0409818A (pt)	2006-05-09	compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
UY30847A1 (es)	2008-05-31	Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
BR0313278A (pt)	2005-07-05	Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo e sua utilização, método para o tratamento e profilaxia de enfermidades e obesidade e utilização dos compostos
BRPI0409878A (pt)	2006-05-23	compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0409881A (pt)	2006-05-23	compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
DE602005010744D1 (de)	2008-12-11	Piperazinylpyridinderivate als mittel gegen adipositas
BRPI0508079A (pt)	2007-07-17	composto ou uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos de tratar ou prevenir uma infecção viral com hepatite c em um mamìfero e de inibir replicação de um vìrus da hepatite c
DE60134735D1 (de)	2008-08-21	Neue neurokinin-antagonisten zum gebrauch als arzneimittel
DE602006020525D1 (de)	2011-04-21	Pharmazeutische Zusammensetzungen zur Verhütung oder Behandlung von Hirnödemen

Legal Events

Date	Code	Title	Description
2011-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties